Information  X 
Enter a valid email address

Company Name matching 'DBV Technologies S.A'

Date
Time Source
Company
Announcement
10 Oct 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)
09 Oct 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
08 Oct 2019 9:18 pm GNW     DBV Technologies S.A. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position
04 Oct 2019 4:45 pm GNW     DBV Technologies S.A. DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
02 Oct 2019 9:00 pm GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
19 Sep 2019 9:00 pm GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
07 Aug 2019 9:05 pm GNW     DBV Technologies S.A. DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
01 Aug 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Reports First Half 2019 Financial Results
18 Jul 2019 6:30 am GNW     DBV Technologies S.A. Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report
12 Jul 2019 11:00 am GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
26 Jun 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer  
11 Jun 2019 1:00 pm GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
03 Jun 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies to Attend Upcoming Investor Conferences
01 Jun 2019 1:00 pm GNW     DBV Technologies S.A. DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
24 May 2019 9:30 pm GNW     DBV Technologies S.A. DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
14 May 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Departure of Deputy CEO David Schilansky
06 May 2019 8:30 am GNW     DBV Technologies S.A. Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting
02 May 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies to Attend Upcoming Investor Conferences
30 Apr 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Reports March 31, 2019 Cash Position
10 Apr 2019 4:00 pm GNW     DBV Technologies S.A. Information regarding the total number of voting rights and total number of shares of the Company
08 Apr 2019 9:30 pm GNW     DBV Technologies S.A. DBV Technologies Announces Closing of Global Offering
  4:00 pm GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
05 Apr 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)
04 Apr 2019 7:00 am GNW     DBV Technologies S.A. DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
03 Apr 2019 9:05 pm GNW     DBV Technologies S.A. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
01 Apr 2019 10:00 pm GNW     DBV Technologies S.A. DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F
06 Mar 2019 6:00 pm GNW     DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company
05 Mar 2019 9:10 pm GNW     DBV Technologies S.A. DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update
  6:30 am GNW     DBV Technologies S.A. DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors
01 Mar 2019 6:30 am GNW     DBV Technologies S.A. DBV Technologies to Attend Upcoming Investor Conferences
22 Feb 2019 4:00 pm GNW     DBV Technologies S.A. DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
13 Feb 2019 9:00 pm GNW     DBV Technologies S.A. DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
08 Feb 2019 3:00 pm GNW     DBV Technologies S.A. DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
04 Feb 2019 9:00 pm GNW     DBV Technologies DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
01 Feb 2019 6:30 am GNW     DBV Technologies DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference
03 Jan 2019 6:30 am GNW     DBV Technologies DBV Technologies Expands and Strengthens Leadership Team
19 Dec 2018 10:00 pm GNW     DBV Technologies DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age
12 Dec 2018 6:30 am GNW     DBV Technologies DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018
20 Nov 2018 6:30 am GNW     DBV Technologies DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
16 Nov 2018 6:30 am GNW     DBV Technologies DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
09 Nov 2018 6:31 am GNW     DBV Technologies DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting
30 Oct 2018 6:30 am GNW     DBV Technologies DBV Technologies Reports September 30, 2018 Cash Position
26 Oct 2018 6:30 am GNW     DBV Technologies DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers
25 Sep 2018 6:30 am GNW     DBV Technologies DBV Technologies to Present at the Cantor Global Healthcare Conference
12 Sep 2018 6:30 am GNW     DBV Technologies DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
07 Sep 2018 6:30 am GNW     DBV Technologies DBV Technologies : Reports First Half 2018 Financial Results
05 Sep 2018 6:30 am GNW     DBV Technologies DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI
31 Aug 2018 6:30 am GNW     DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
27 Jul 2018 6:30 am GNW     DBV Technologies DBV Technologies Reports June 30, 2018 Cash Position
26 Jul 2018 6:30 am GNW     DBV Technologies DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
22 Jun 2018 9:00 pm GNW     DBV Technologies DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
05 Jun 2018 6:30 am GNW     DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
01 Jun 2018 6:30 am GNW     DBV Technologies DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting
29 May 2018 6:30 am GNW     DBV Technologies DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018
16 May 2018 6:30 am GNW     DBV Technologies DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
14 May 2018 1:31 pm GNW     DBV Technologies DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week
08 May 2018 6:30 am GNW     DBV Technologies DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting
01 May 2018 6:30 am GNW     DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
03 Apr 2018 6:30 am GNW     DBV Technologies DBV Technologies to Attend the 11th Kempen Life Sciences Conference


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t